BioSpace News Archive

Proteintech Group, Inc, the benchmark in antibodies and proteins, announces completion of its ISO 13485 certification for medical devices. With this certification, Proteintech’s HumanKine® Human cell-expressed cytokines and growth factors are now available in GMP-compliant versions for use in clinical trials and commercial manufacturing

Initiation of intravenous Factor VIII treatment in early childhood improves joint outcomes in young adulthood

Epigenetics company Base Genomics launches, based on a new invention to sequence DNA methylation developed at the Ludwig Institute for Cancer Research Branch at the University of Oxford

Karuna Therapeutics, Inc. announced that Steve Paul, M.D., chief executive officer, president and chairman of Karuna Therapeutics, will participate in a fireside chat at the virtual Goldman Sachs Annual Global Healthcare Conference on Thursday, June 11, 2020 at 10:30 a.m. EDT.

Thomas Powell, Executive Vice President and Chief Financial Officer, Teleflex Incorporated, is scheduled to speak at the Raymond James 2020 Human Health Innovation Conference on Wednesday, June 17, 2020 at 2:20 p.m..

Long-term results from SPIRIT-H2H show robust efficacy of Taltz as monotherapy or in combination with methotrexate or additional csDMARDs

Eli Lilly and Company will present new data for Olumiant® at the virtual European Congress of Rheumatology taking place June 3-6, 2020.

AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization, has announced that it will partner with Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, on large-scale GMP production of a critical component of Novavax’ coronavirus vaccine candidate, NVX-CoV2373.

Pluristem Therapeutics Inc., a leading regenerative medicine company developing a platform of novel biological products, announced that it was selected as a member of the CRISPR-IL consortium, a group funded by the Israeli Innovation Authority.

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announced today its participation in the CRISPR-IL consortium